20 articles
Fisetin is emerging as a top senolytic candidate, clearing senescent cells linked to aging — and strawberries are its richest dietary source.
ProJenX completes enrollment for Prosetin's Phase 1b ALS trial, reporting strong safety data and target engagement at therapeutic doses.
A UC San Diego trial shows ION224 blocks liver fat production, cutting inflammation and scarring in 60% of MASH patients.
A major RCT shows finerenone reduces kidney function loss by 23% in non-diabetic CKD patients, expanding its protective role beyond diabetes.
Experimental diabetes drug IC7Fc reduces cholesterol and artery plaque buildup, offering cardiovascular benefits even without weight loss.
Sironax's SARM1 inhibitor SIR2501 wins FDA Fast Track status for chemotherapy-induced nerve damage, with trials also targeting ALS.
Phase II trial shows petrelintide, a weekly amylin injectable, achieves meaningful weight loss with far fewer nausea and vomiting events than GLP-1 drugs.
Insilico Medicine's AI-generated TNIK inhibitor enters Phase 1 trials for pulmonary fibrosis, signaling a new era in drug discovery.
AT7687 blocks fat storage signals rather than suppressing hunger, showing early safety wins and metabolic benefits in first-in-human data.
OrsoBio's mitochondrial drug TLC-6740 added 4.5% more weight loss on top of tirzepatide in a Phase 2a trial, with bonus metabolic and cognitive benefits.
FORZINITY becomes the first FDA-approved therapy targeting mitochondria directly, launching for Barth syndrome patients amid a company rebrand.
A BET inhibitor called RVX-208 reprogrammed diseased perivascular fat, restoring blood vessel function in obese hypertensive patients.
OrsoBio's oral TLC-6740 paired with tirzepatide boosted weight loss by an extra 4.5% in 24 weeks, with gains in insulin sensitivity and liver health.
Scientists discover vitamin B3 can target a key genetic driver of fatty liver disease, offering hope for 30% of people affected globally.
Researchers identified polyunsaturated fatty acids that may help eliminate senescent cells linked to aging and disease.
A novel antibody targeting inflammation in diabetic eye disease enters Phase 1b trials, with early data expected by end of 2026.
ATX-304 raised resting metabolic rate 8%, slashed triglycerides, and reduced liver fat in an 8-week Phase 1b trial for prediabetes.
Tirzepatide outperforms semaglutide on weight loss but may strip more muscle. Plus: fructose, keto diets, and cardiac benefits of oral GLP-1s.
Annovis's buntanetap reduced tau and neuroinflammation markers while improving cognition in mild Alzheimer's patients across a 12-week trial.
Cambrian Bio's ATX-304 reduced liver fat, visceral fat, and raised resting metabolic rate by 8% in a Phase 1b trial of adults with prediabetes.
